Checking Saved…Welcome – and thank you – for signing up for Apria monthly newsletters!Captured October 20, 2026·WelcomeCreate this for my brand
Checking Saved…TPTakeda PharmaceuticalFirst and Only Ulcerative Colitis Treat-to-Target Trial Shows Treating to Disease Clearance vs. Symptomatic Remission with ENTYVIO® (vedolizumab) Prolongs Time to First Disease-Related ComplicationCreate this for my brand
